Current developments in pharmacological therapeutics for chronic constipation  by Jiang, Chunhuan et al.
Institute of Materia Medica, Chinese Academy of Medical Sciences
H O S T E D  B Y Chinese Pharmaceutical Association
www.elsevier.com/locate/apsb
Acta Pharmaceutica Sinica B
Acta Pharmaceutica Sinica B 2015;5(4):300–309http://dx.doi.org/10.10
2211-3835 & 2015 Ch
Elsevier B.V. This is
Abbreviations: 5-H
ﬁbrosis transmembran
GC-C, guanylate cycl
sodium-dependent bile
pill; NHE3, sodium-hy
G-protein-coupled bile
nCorresponding aut
E-mail addresses:
Peer review under rwww.sciencedirect.comREVIEWCurrent developments in pharmacological
therapeutics for chronic constipationChunhuan Jiang, Qinglong Xu, Xiaoan Wenn, Hongbin SunnState Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease,
China Pharmaceutical University, Nanjing 210009, China
Received 19 November 2014; received in revised form 20 January 2015; accepted 26 February 2015KEY WORDS
Chronic constipation;
Prokinetic agent;
5-HT4 receptor;
Prosecretory agent16/j.apsb.2015.05.00
inese Pharmaceutica
an open access artic
T, serotonin; CaCC
e conductance regul
ase C; GI, gastroint
acid transporter); IB
drogen exchanger 3
acid receptor
hors. Tel./fax: þ86 2
wxagj@126.com (X
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including lubiprostone, linaclotide and prucalopride have been approved for treatment of chronic
constipation. However, a signiﬁcant unmet medical need still remains, particularly among those patients
achieving poor results by current therapies. The 5-HT4 receptor modulators velusetrag and naronapride,
the guanylate cyclase C agonist plecanatide and the ileal bile acid transporter inhibitor elobixibat are
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the pharmacological therapeutics for the treatment of chronic constipation, with the purpose of reﬂecting
the drug development trends in this ﬁeld.
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Chronic constipation (CC) is a common gastrointestinal disorder in
which patients have unsatisfying defecation associated with
infrequent bowel movements (o3 bowel movements per week),
hard stools and straining when passing stool, even compounded
with abdominal discomfort and bloating1. It was estimated that
constipation has a prevalence range from 8.75% in the Asian
Paciﬁc region to 27% in Western countries2. Constipation in
women occurs twice as frequently as in men. Severe constipation
(e.g., only twice bowel movements a month) almost extensively
occurs in women3. Constipation heavily impacts the patient's
quality of life4. In addition to the direct economic burden caused
by treatment, patients may face hardships such as missing school
or work5. Inadequate intake of dietary ﬁber, lack of exercise,
intestinal dysfunction, etc. can cause constipation. However,
chronic primary or chronic idiopathic constipation (CIC), which
is typically classiﬁed into three categories: outlet obstruction,
normal-transit constipation and slow colonic transit6, has no
deﬁnitive cause. For the initial treatment of chronic constipation,
increasing ﬁber intake or using lavatives is commonly recom-
mended. Although clinical trials show that most lavatives achieve
poor results, new pharmacological therapies with different
mechanisms of action have been developed over the last decade
for the treatment of chronic constipation.2. Prokinetic agents
Main investigational prokinetic agents for the treatment of chronic
constipation are listed in Table 1. Their mechanisms of action are
illustrated in Fig. 1. 5-HT4 agonists and motilin agonists, acting on
5-HT4 receptors or motilin receptors located on epithelium,
smooth muscle cells and intrinsic primary afferent neurons
(IPAN), can directly or indirectly initiate the peristaltic or
secretory reﬂex through the release of acetylcholine, resulting in
decreased colonic transit time, improved bowel movement fre-
quency and ameliorative bowel satisfaction7.
2.1. 5-HT4 agonists
Serotonin (5-HT) is involved in gastrointestinal secretion, sensa-
tion and motility. It was estimated that 95% of 5-HT is distributed
in the enteroendocrine cells of gastrointestinal (GI) mucosa.Table 1 Prokinetic agents for the treatment of chronic constipation.
Agent Class Company
Tegaserod 5-HT4 agonist Novartis
Prucalopride 5-HT4 agonist Movetis, Janssen
Velusetrag 5-HT4 agonist Theravance, Alfa Wasserman
Naronapride 5-HT4 agonist Armetheon
YKP10811 5-HT4 agonist SK Biopharm
TD-8954 5-HT4(c) agonist Theravance
Mitemcinal
fumarate
Motilin agonists Chugai PharmaAmong the seven subtypes of 5-HT receptors8, the gastrointestinal
5-HT4 receptor is an extensively studied target for prokinetics.
Early 5-HT4 receptor agonists (e.g., tegaserod and cisapride)
generally have low afﬁnity and poor selectivity for the 5-HT4
receptor, accounting for poor efﬁcacy and relatively serious
adverse effects. More recently, many highly selective 5-HT4
receptor agonists (Fig. 2) have been investigated and may have
a good proﬁle of cardiovascular safety9.
2.1.1. Prucalopride
Prucalopride (1, RO93877), initially developed by Janssen Pharma-
ceuticals, is presently licensed by Movetis to develop this agent as an
orally administered, ﬁrst-in-class drug for treatment of severe chronic
constipation. As a very highly selective 5-HT4 agonist, prucalopride
has no measurable afﬁnity for other receptors. In safety evaluation
tests, prucalopride showed no hERG (human ether-à-go-go-related
gene) channel inhibitory activity. At dosages of 2 mg and 4 mg per
day, this drug produced a low incidence of QT interval prolongation.
Even up to 20 mg per day (10-fold higher than the recommended
dosage), prucalopride displayed no clinically relevant effects on
cardiovascular parameters in healthy volunteers. Prucalopride
improved stool frequency and consistency, and dose-dependently
enhanced colonic transit in healthy controls or chronic constipation
patients with no negative impact on gastric emptying or small bowel
transit10. The patient0s quality of life was signiﬁcantly improved by
prucalopride treatment. Prucalopride was well absorbed from the
gastrointestinal tract, with an absolute oral bioavailability of more
than 90%. Its main elimination route was via the urine (60%–70%
excreted unchanged in the urine). Because prucalopride has a low
level of metabolism by liver, its pharmacokinetics is unlikely to be
altered by hepatic impairment and no CYP3A4 drug interactions are
anticipated. In Europe, 2 mg of prucalopride has been approved for
the treatment of chronic constipation in women who have no
adequate response to laxatives11.
2.1.2. Velusetrag
Velusetrag (2, TD-5108) is an orally administrated available 5-HT4
agonist developed by Theravance. Binding afﬁnity of this drug for the
5-HT4 receptor is over 500-fold that of other 5-HT receptor subtypes
12.
HRX-830449, the active metabolite of velusetrag, has a similar afﬁnity
and selectivity for 5-HT4. Increased smooth muscle contractility of the
antrum, fundus, duodenum and jejunum was observed in velusetrag-
treated dogs13. The relief of constipation by velusetrag was also
conﬁrmed in chronic constipation patients14. The most common adverseClinical consideration Status
Cardiovascular problem Withdrawn in 2007
Accelerate colonic transit Marketed in EU, Canada
Accelerate colonic transit Phase II
Accelerate colonic transit Phase II, but not active
Improve gastric emptying,
accelerate colonic transit
and reduce visceral pain
Phase I
Increase bowel movement frequency,
reduce time to ﬁrst stool and
cardiovascular risk
Phase II
Strongly promote peristalsis Preclinical
Figure 2 Chemical structures of 5-HT4 agonists.
Figure 1 Action mechanism of prokinetic agents in gastrointestinal tract.
Chunhuan Jiang et al.302effects of velusetrag were those frequently associated with 5-HT4
agonists, including diarrhea, headache and nausea. These dose-
dependent adverse effects were mild to moderate, and usually occurred
within the initial days of dosing. Clinically relevant doses of velusetrag
in animals or humans did not generate severe side effects on blood
pressure, heart rate or electrocardiogram. In isolated porcine or canine
coronary arteries, velusetrag showed no contractile activity15.
2.1.3. Naronapride
Naronapride (3, ATI-7505) activates 5-HT4 receptors but has
almost no actions on the other 5-HT subtypes. Moreover, the
hERG channel inhibitory activity of this compound is negligible.A thorough QT study showed that naronapride had no obvious
effect on cardiac repolarization at either therapeutic or suprather-
apeutic doses16. ATI-7500, the main metabolite of naronapride, is
100-fold less active than the parent drug. Unlike prucalopride
and velusetrag, both naronapride and ATI-7500 cannot pass the
blood-brain barrier, therefore reducing the incidence of side
effects. In a clinical trial Phase IIa, naronapride accelerated the
stool consistency and colonic transit and promoted colonic
emptying in healthy volunteers. In a 4-week Phase IIb clinical
trial, 20–120 mg of naronapride twice a day led to a greater mean
number of completely spontaneous bowel movements than pla-
cebo. A higher dose, 80 mg twice daily, achieved the best effect17.
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TD-8954 (4, also developed by Theravance) is highly selective for
the 5-HT4c receptor, with the binding afﬁnity 2000-fold stronger
than for the other 5-HT receptors and non-serotonin receptors.
TD-8954 showed no hERG channel inhibitory activity and no
signiﬁcant off-target effect. Preclinical trials showed that doses as
low as 0.1 mg of TD-8954 produced prokinetic effects and 0.5 mg
attained a maximal response. Increased colonic transit was
observed in TD-8954 treated animals (0.03 mg/kg). Compared
with tegaserod, cisapride and mosapride, TD-8954 more potently
inhibited spontaneous and electrically-evoked contractions in the
healthy human colon. TD-8954 was also able to increase bowel
movement frequency and reduce the time to ﬁrst stool18.Figure 3 Chemical structu
Table 2 Prosecretory agentsa.
Agent Class Company Clinical co
Lubiprostone ClC-2 activator,
EP4 agonist
Takeda Accelerate
and colon
abdomina
and cons
(24 mg tw
Misoprostol Synthetic PGE2
analogue
Pﬁzer Increase ﬂ
improve
stool wei
movemen
Linaclotide GC-C agonist Ironwood, Forest Accelerate
and bowe
and act lo
(once-dai
Plecanatide GC-C agonist Synergy 8-fold mor
non-syste
once-dail
Sodium
chenodeoxycholate
Bile acid analogue Mayo Clinic Enhance c
and muco
and incre
Elobixibat IBAT inhibitor Albireo, Ferring Act locally
minimal
modulate
and incre
aCIC: chronic idiopathic constipation; OIC: opioid-induced constipation;
dependent bile acid transporter); IBS-C: irritable bowel syndrome with con2.2. Motilin agonists
Motilin, an endogenous 22–amino acid peptide hormone secreted
from the enterochromafﬁn cells of the small intestine, is cyclically
released during the interdigestive state to initiate well-coordinated
gastrointestinal contraction. By acting on the G-protein coupled
motilin receptor (expressed on the smooth muscle cells of gastro-
intestinal tract and the enteric nervous system), motilin can improve
the delay in gastric emptying associated with many types of illness19.
Erythromycin (5, Fig. 3) is a typical macrolide-type antibiotic
widely used for decades. In clinical use of erythromycin as an
antibiotic drug, it was found that erythromycin could accelerate the
gastric emptying in patients with gastroparesis and stimulated theres of motilin agonists.
nsideration Status
of small bowel frequency
ic transit, and improve
l bloating, discomfort
tipation severity ratings
ice-daily capsule)
Marketed for CIC,
IBS-C and OIC
uid and bicarbonate secretion,
colonic transit time,
ght and bowel
t frequency
No development reported
colonic transit
l movement frequency,
cally in the intestine
ly capsule)
Marketed for CIC
and IBS-C in USA
e potent than uroguanylin,
mic distribution,
y oral tablet
Phase III (CIC)
olonic motility
sal permeability,
ase mucus secretion
Phase II (IBS-C)
in the gut with
systemic exposure,
enterohepatic circulation of bile acids,
ase colonic ﬂuid secretion and motility
Phase III (CIC)
IBAT: the ileal bile acid transporter (also known as the apical sodium-
stipation; GC-C: guanylate cyclase C.
Chunhuan Jiang et al.304myoelectric complex to migrate in the fasting small intestine20.
Preliminary studies showed that oral administration of erythromy-
cin could increase the stool frequency and decrease the colonic
transit time in healthy volunteers or patients with idiopathic
constipation21. These ﬁndings motivated people to discover non-
antibiotic macrolide as promotility agents. Mitemcinal fumarate (6,
GM-611), an acid-stable erythromycin derivative with very weak
antibiotic activity, was identiﬁed as a potent motilin agonist22. It is
being developed in clinical phase II for the treatment of irritable
bowel syndrome, non-ulcer dyspepsia and diabetic gastroparesis. It
was also suggested that mitemcinal fumarate should be considered
for the treatment of chronic constipation. Studies demonstrated
that GM-611 could stimulate and promote the peristalsis of
gastrointestinal tract. Oral administration of GM-611 (2.5–
10 mg/kg) in normal rabbits produced sustained depolarization
of the duodenal smooth muscle and increased stool weight in a
dose-dependent manner without causing loose stools23. In con-
scious dogs, GM-611 (0.3–3 mg/kg) reduced the time to ﬁrst
bowel movement without inducing diarrhea.3. Prosecretory agents
Main investigational prosecretory agents for the treatment of chronic
constipation are listed in Table 2. Their mechanisms of action are
summarized in Fig. 4. Activation of the GC-C receptor can promote
intracellular synthesis of cGMP and subsequently stimulates the
cGMP-dependent protein kinase II (PKGII) to phosphorylate CFTR,
thereby increasing chloride secretion and paracellular movement of
sodium and water into the intestinal lumen. cGMP is also able to
inhibit the sodiumhydrogen exchanger NHE3, thereby decreasing
sodium absorption. Lubiprostone can induce chloride secretion intoFigure 4 Mechanism of prosecretoryintestinal lumen by opening of the CLC-2 chloride channel.
Misoprostol and lubricating gut pills (LGP) can activate EP2/4
receptors to stimulate cAMP production with a resultant increase in
chloride secretion. Elobixibat inhibits ileal bile acid reabsorption to
increase bile acid load into the colon. The increasing bile acid
enhances colonic electrolyte secretion by acting with TGR5 on
enterocytes, thus stimulating cAMP generation and electrogenic
chloride secretion. EPX-16006 activates the colonic P2Y2 receptor
to open the calcium-activated chloride channel (CaCC), increase the
production and release of PGE2, and subsequently trigger chloride
secretion. The P2Y2 receptor also plays a role in the inhibition of
amiloride-sensitive sodium transport via the epithelial sodium
channel (ENaC). The end results of both mechanisms are the
preservation of intestinal water and prokinesis of the luminal
contents.3.1. Chloride channel activators
Chloride channels are involved in a wide range of biological
functions including epithelial ﬂuid secretion and smooth-muscle
contraction24. Chloride secretion (Fig. 4) is the major determinant
of mucosal hydration throughout the gastrointestinal tract, and
chloride transport is also pivotal in the regulation of ﬂuid secretion
into the intestinal lumen25. Two speciﬁc chloride channels ClC-2
(chloride channel protein 2) and CFTR (cystic ﬁbrosis transmem-
brane conductance regulator) have been validated as targets for the
treatment of constipation26.
ClC-2 has been localized on gastrointestinal parietal cells and
small and large intestinal epithelial cells27. Activity of the ClC-2
channel enables pass of chloride ions across the cellular membrane
and subsequent release of sodium and water through paracellularagents in the gastrointestinal tract.
Figure 5 Chemical structures of prosecretory agents.
Current developments in pharmacological therapeutics for chronic constipation 305pathways into the intestinal lumen. The luminal distension caused
by increased intestinal ﬂuid promotes the gastrointestinal tract
motility, thereby increasing intestinal and colonic transit. Once this
isotonic solution reaches the colon, the colon reabsorbs the excess
ﬂuid, resulting in more frequent bowel movements. However,
ClC-2 was also found on the basolateral membrane of distal
colonic epithelial cells in guinea-pigs28. There is another opinion
that ClC-2 channels may serves as an exit pathway for Cl in the
basolateral membranes of the distal colon.
Lubiprostone (7, Fig. 5), a ﬁrst-in-class drug for the treatment of
chronic idiopathic constipation and irritable bowel syndrome in
adult constipation women, is believed to be a highly selective
locally-acting activator of ClC-2 channels27. Lubiprostone can
tautomerize between the inactive form I and the active form II29.
However, controversy still remains on the mechanism of action of
lubiprostone30. There is now considerable evidence that lubipros-
tone primarily activates CFTR by binding to the basolateral
prostaglandin receptor EP431.
Lubiprostone has low systemic bioavailability due to its high
lipophilicity. The plasma concentration of lubiprostone is too low
to be quantiﬁed. The absorbed lubiprostone is rapidly and
extensively metabolized by microsomal carbonyl reductase in the
stomach and jejunum to form the metabolite M3, which is the only
measurable metabolite in blood29. Several large trials proved thatlubiprostone could increase the number of spontaneous bowel
movements (SBMs), improve the stool consistency and reduce
straining, bloating and the overall constipation symptoms in
chronic constipation patients and irritable bowel syndrome patients
complicated with constipation32. Lubiprostone (24 μg twice daily)
has been approved by the US. FDA for women and men with
chronic constipation. A lower dose (8 μg) has been approved for
irritable bowel syndrome with constipation in woman. Lubipros-
tone is also beneﬁcial for patients with opioid-induced constipa-
tion. The common and dose-dependent side-effects of lubiprostone
include nausea, headache and diarrhea.3.2. PGE2 receptor agonist
Postaglandins E2 and E1 (PGE2 and PGE1) can activate the
prostaglandin receptors EP2/4 and subsequently stimulate cAMP
production. These actions increase ﬂuid and bicarbonate secretion
in the small intestine, which are clinically beneﬁcial for patients
with chronic constipation. It was demonstrated that PGE1 caused a
net ﬂuid secretion in the canine small intestine33 and PGE2
decreased sodium absorption and increased chloride secretion in
human jejunum34.
Chunhuan Jiang et al.306Misoprostol (8, Fig. 5) was approved by the U.S. FDA for the
prevention of nonsteroidal anti-inﬂammatory drug-induced gastric
ulcers. In clinical use, it was found that misoprostol could cause
diarrhea. Further studies showed that misoprostol could activate
EP2, EP3 and EP4 receptors. In a small trial involving nine
patients with severe chronic constipation, misoprostol (1.2 mg per
day) was able to stimulate mucosal water and ion secretion,
increase the weight and frequency of stools, and shorten colonic
transit time35,36. However, high doses of misoprostol caused
abdominal cramping, bloating and nausea. In addition, adminis-
tration of misoprostol to women of child-bearing age could lead to
spontaneous abortion, premature birth or birth defects. For these
reasons, the U. S. FDA did not approve misoprostol for any
constipation.
3.3. Uroguanylin and GC-C receptor agonists
Uroguanylin (16 amino acids) and guanylin (15 amino acids) are
small cysteine-rich peptide hormones predominantly secreted and
locally acting in the intestinal tract. These agents bind to a unique
receptor found on the intestine epithelial cells, called guanylate
cyclase C (GC-C, also known as STA receptor)37. GC-C plays
key roles in the regulation of intestinal ﬂuid and electrolyte
homeostasis. Activation of the GC-C receptor promotes intracel-
lular synthesis of cGMP and subsequent activation of CFTR,
resulting in chloride and bicarbonate secretion as well as para-
cellular movement of sodium and water into the intestinal lumen.
These changes in the intraluminal milieu facilitate the ﬂuid
movement into the gut lumen, leading to improved transit of fecal
materials through the lower gastrointestinal tract to facilitate
defecation.
3.3.1. Linaclotide acetate
Linaclotide acetate (9, MD-1100) is an orally administered available
ﬁrst-in-class 14–amino acid peptide with three disulﬁde bonds, which
is being developed by Microbia Inc. for the treatment of constipation,
predominant irritable bowel syndrome, and chronic idiopathic con-
stipation. Linaclotide acts as an agonist of GC-C and also inhibits the
sodium absorption from lumen via a sodium proton exchanger. The U.
S. FDA has approved 290 μg of linaclotide daily for irritable bowel
syndrome with constipation and 145 μg daily for chronic idiopathic
constipation38. The company may, according to the recent preclinical
studies, expand the therapeutic range to post-operative ileus and opioid-
induced constipation. Linaclotide-potently and pH-independently binds
to GC-C receptors in human colon carcinoma T84 cells (Ki¼1.23–
1.64 nmol/L), resulting in a signiﬁcant, concentration-dependent accu-
mulation of intracellular cGMP (EC50¼99 nmol/L). Linaclotide was
observed to function locally in the lumen. Pharmacokinetic analysis
showed that linaclotide had very low oral bioavailability (0.1%), and
was undetectable in the systemic circulation at therapeutic doses. In a
rat model, oral linaclotide dose-dependently increased intestinal secre-
tion, improved gastrointestinal transit and lowered the visceral percep-
tion of pain39. Johnston and colleagues40 were the ﬁrst to investigate
the safety, tolerability and efﬁcacy of linaclotide in patients with
chronic constipation who met modiﬁed Rome II criteria. This multi-
center, placebo-controlled pilot study published in 2009, showed that
there was a trend towards a dose-dependent increase in the frequency
of weekly SBM. Linaclotide accelerated colonic transit, enhanced
intestinal secretion and improved symptoms in patients with chronic
constipation. The adverse effects were primarily diarrhea and other
gastrointestinal symptoms. Linaclotide is acid-stable and resistant toaminopeptidase and chymotrypsin under non-reducing conditions, but
is degraded rapidly in the duodenum by the carboxypeptidase. This
results in loss of the C-terminal tyrosine, and formation of the active
13–amino acid metabolite, MM-419447. MM-419447 also stimulates
the accumulation of cGMP in T84 cells and accelerates gastrointestinal
transit in rats41. The binding afﬁnity of MM-419447 for GC-C on T84
cells and rat small intestine brush-border membranes was comparable
to that of linaclotide.3.3.2. Plecanatide
Plecanatide (10, SP-304) is an orally available synthetic analogue
of uroguanylin under development by Synergy Pharmaceuticals
Inc. for the treatment of chronic constipation and irritable bowel
syndrome with constipation. Plecanatide mimics the endogenous
agonist of GC-C receptor in the intestinal tract. Like that of
uroguanylin, plecanatide's actions are pH-dependent, with most
favorable efﬁcacy in the acidic environment of the duodenum.
Similar to lincaclotide, plecanatide luminally activates the GC-C
receptor on gastrointestinal mucosal epithelial cells, leading to
intracellular secretory and extracellular anti-nociceptive effects via
a cGMP mediated second messenger pathway42. Plecanatide
potentially has low risk of cadiovaslular adverse effects as its
systemic absorption is very low. According to the phase I study for
evaluation of the safety and tolerability of plecanatide in
humans43, no measurable systemic absorption was observed at
any doses of oral plecanatide. Plecanatide was safe and well
tolerated up to the highest dose. Diarrhea was the most prevalent
side effect, but its frequency did not statistically signiﬁcantly differ
between placebo and plecanatide, and appeared not to be dose-
related in the plecanatide-treated subjects. Other gastrointestinal
events were nausea, abdominal discomfort and pain, and vomiting.
In a Phase IIa dose escalation trial involving a total of 84 chronic
constipation patients recruited with modiﬁed Rome III criteria, 14
days of plecanatide therapy improved stool frequency, stool
consistency, straining and overall relief of chronic constipation
symptoms. To conﬁrm the safety and efﬁcacy of plecanatide,
two Phase III trials (NCT01982240 and SP304203-00) have been
planned. In the US and Canada, the Phase III trial NCT01982240
was initiated in November 2013 with adult chronic constipation
patients and was expected to complete in February 201544.3.4. Increasing colonic bile acids
Bile acids including chenodeoxycholic acid (CDCA) and cholic acid
are synthesized in the liver through hydroxylation and conjugation of
cholesterol to hydrophobic primary bile acids25. Normally, up to 95%
of intestinal bile acids are reabsorbed by ileal bile acid transporters
located in the terminal ileum and returned to the liver via the portal
vein (enterohepatic circulation). Therefore, under normal circum-
stances, only small quantities of bile acids spill over to the colon45,
where bile acids are deconjugated and dehydroxylated by colonic
microbiota to produce secondary bile acids such as deoxycholic acid.
However, if ileal function is compromised by either resection or
disease, reabsorption of bile acids would be inadequate and therefore
delivery of bile acids into the colon increases to induce mucus
production, colonic motility and stimulate defecation. Bile acids can
induce colonic electrolyte secretion by acting on the membrane-
bound bile acid GPBA receptor (TGR5) on enterocytes (Fig. 4) and
subsequently leading to stimulation of cAMP generation and electro-
genic chloride secretion. Thus, supplementation of speciﬁc bile acid
Current developments in pharmacological therapeutics for chronic constipation 307analogues or use of drugs that inhibit ileal bile acid reabsorption may
beneﬁt constipation patients.
3.4.1. Sodium chenodeoxycholate
Bile acids such as chenodeoxycholic acid (CDCA), previously used for
dissolution of gallstones, are known to elicit diarrhea at high doses in
healthy controls and constipation patients46. The effects of CDCA on
gastrointestinal and colonic function have been evaluated in healthy
volunteers and patients with irritable bowel syndrome with constipa-
tion. In a randomized controlled trial, CDCA 500 mg and 1000 mg
given to 60 healthy volunteers for 4 days led to dose-dependent
acceleration of colonic transit. In addition, signiﬁcant increases in stool
frequency, decreases in stool consistency, and improvements in ease of
stool passage were reported with CDCA47. Rao et al.48 showed in a
double-blind placebo-controlled study that sodium chenodeoxycholate
(11) accelerated colonic transit and improved bowel function in 36
female patients with irritable bowel syndrome with constipation.
Increased stool frequency, greater ease of stool passage and looser
stool consistency were observed in patients treated with sodium
chenodeoxycholate 500 mg or 1000 mg for 4 days as compared with
controls. Unfortunately, over 40% of sodium chenodeoxycholate
treated patients had light abdominal cramping or pain. Whether
these side effects could be mitigated at a lower dose remains to be
determined.
3.4.2. Elobixibat
Elobixibat (12) is an orally administrated available potent inhibitor of
ileal bile acid transporter with minimal systemic exposure49. It is
under development by Albireo AB and Ferring Pharmaceuticals Inc.
for the treatment of chronic constipation. Elobixibat dose-dependently
inhibited the reabsorption of bile acids and thus increased the delivery
of bile acids to the proximal colon, which in turn increased ﬂuid
secretion, colonic motility and stool frequency, and also improved
stool consistency and relieved constipation-related symptoms in
chronic idiopathic constipation patients50,51. According to the results
of Phase II trials in chronic idiopathic constipation patients, elobixibat
was safe and generally well-tolerated, even at the dose up to 20 mg
per day. Elobixibat was found to decrease the time to complete
spontaneous bowel movement in dose-dependent manner. Elobixibat
also signiﬁcantly relieved constipation-related symptoms such as
stool consistency, straining on evacuation and abdominal bloating,
according to the claims of several patients. Chronic constipation
patients with dyslipidemia might specially beneﬁt from elobixibat
because it has the potential to lower plasma lipid levels by the
shunting of cholesterols. To support this point, further validation
studies should be conducted49. The side effects of elobixibat are
mainly gastrointestinal tract–related. Although higher dosages of
elobixibat caused abdominal pain and diarrhea more frequently, no
severe adverse effects occurred in the Phase I and Phase II clinical
trials. The Phase III clinical trials are ongoing to determine the best
tolerated dose and to examine the effects of long-term administration.
As illustrated by elobixibat, the advantages of IBAT inhibitors may
be especially attractive, which may boost the research of other IBAT
inhibitors, for example, SC-435, S-8921 and S-096052–54.4. Traditional Chinese medicines
Hemp seed extract as a popular Chinese herbal medicine is often used
for the treatment of constipation55. In a 8-week trial with 120
constipation patients56, 43.3% of patients treated with 7.5 g of hemp
seed pill twice daily had a mean increase in the number of completelyspontaneous bowel movements (Z1/week). Moreover, 30% of hemp
seed pill treated patients had a sustained increase in the frequency of
completely spontaneous bowel movements. The constipation symp-
toms and severity was obviously relieved in hemp seed treated
patients, and no serious adverse effects took place. In addition, Wu
et al.57 recently demonstrated that a traditional Chinese formula, LGP,
could generate laxative effect in loperamide-induced constipation rats.
LGP increased the production of endogenous PGE2 in colonic
mucosa via activation of EP4 receptor.5. Other agents
KWA-0711, developed by Kissei Pharmaceutical Co., Ltd., can
inhibit water absorption in the gastrointestinal tract58. Several phase II
clinical trials have been conducted in Japan to evaluate the efﬁcacy
and safety of KWA-0711 in constipation patients. However, the clear
action mechanism of KWA-0711 is unknown. And, to date, there is
no clinical trial result of KWA-0711 published.
A luminally active dinucleotide mimic MDT-006 (formerly
EPX-16006) is under investigation by the MicroDose Therapeutx
as a ﬁrst-in-class oral drug for the treatment of chronic constipa-
tion. It was reported that MDT-006 is a non-absorbable highly
selective P2Y2 agonist, which stimilated chloride secretion in gut
lumen59. Preclinical trials demonstrated that MDT-006 dose-
dependently reduced the total gastrointestinal transit time,
improved the gastrointestinal motility and increased the production
of feces and its water content with no effect on the gastric
emptying. In January 2013, this drug candidate was ready for
phase I development. Because MDT-006 is not absorbed and its
action site is restricted to the colon, it was estimated that MDT-006
might have a good proﬁle of safety and tolerability, with the
incidence of nausea and systemic liabilities reduced60.
Colchicine, usually used as an anti-inﬂammatory drug, has also been
investigated in the management of chronic constipation. In clinical use
of colchicine as an anti-inﬂammatory drug, patients were found to often
suffer from diarrhea. Further study demonstrated that colchicine could
stimulate the intestinal motility and the myoelectric activity in rats.
Colchicine was also able to reduce intestinal absorption and increase
intestinal secretion in a cAMP-mediated manner, resulting in a net
increase of intestinal secretion61. In a randomized, double-blind and
placebo-controlled crossover trial, oral administration of colchicine
0.6 mg three times daily increased the frequency of bowel movement
and accelerated the colonic transit in refractory constipation patients62.
In another randomized, double-blind and placebo-controlled study,
colchicine was demonstrated to be effective for the treatment of slow
transit constipation. It was found that 1 mg of colchicine per day
caused a signiﬁcant increase in the number of spontaneous bowel
movements and an obvious improvement in the patient's symptoms63.
Unfortunately, increased occurrence of abdominal pain was observed
in the colchicine group. In addition, long-term use of colchicine may
cause granulocytopenia, renal dysfunction, reversible myopathy or
neuropathy and hepatitis. Thus, further long-term study is necessary
before it could be recommended for long-term use.6. Conclusions
Traditional laxatives are widely used and commonly recommended for
the initial treatment of chronic constipation. Unfortunately, most of
them showed poor effects in clinical evaluation trials. Thus, new
pharmacological therapeutics are needed to achieve substantial relief of
Chunhuan Jiang et al.308constipation symptoms and normalization of gastrointestinal motility.
Tegaserod and cisapride as prokinetic drugs have never been approved,
but withdrawn from the market because of their cardiotoxic adverse
effects. New prokinetic drugs with potent intrinsic activity, high
selectivity and low cardiotoxic effects may be clinically available in
the coming years. Luminally acting agents, e.g., lubiprostone, are also
promising because they could improve not only intestinal motility but
also secretion in small bowel or colon with low risk of causing non-
gastrointestinal adverse effects. In the meantime, current drugs need to
be further studied. For example, the active ingredients of lubiprostone
are yet unknown.Acknowledgments
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